Advertisement Adapt Pharma gets FDA fast track status for intranasal naloxone to treat opioid overdose - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Adapt Pharma gets FDA fast track status for intranasal naloxone to treat opioid overdose

US-based biopharmaceutical firm Lightlake Therapeutics' partner Adapt Pharma has received fast track designation from the US Food and Drug Administration (FDA) for intranasal naloxone treatment to reverse opioid overdose.

Lightlake is focused on developing addiction treatments based on its expertise in opioid antagonists.

In December 2014, Lightlake in partnership with the National Institute on Drug Abuse (NIDA), a part of the National Institutes of Health (NIH) started a clinical trial to test the new intranasal delivery system for the delivery of naloxone.

According to the trial, the new intranasal naloxone is expected to prevent opioid overdose deaths, a public health problem of epidemic proportions in the US.

Lightlake CEO Dr Roger Crystal said: "We are very pleased the FDA granted Fast Track designation to Adapt Pharma for the intranasal naloxone treatment to reverse opioid overdose.

"The decision reflects the critical need for better delivery of and access to naloxone. Too many lives have been lost by opioid overdose and we look forward to this novel technology being available to patients and bystanders in the US.

As part of a licensing deal with a subsidiary of Adapt Pharma in December 2014, Lightlake is expected to receive potential development and sales milestone payments of more than $55m, plus up to double-digit royalties.